Bitcoin's 7-day moving average of Open Interest fell below its 365-day average in early October, signaling cautious speculative interest despite recent price gains. Spot Bitcoin ETF outflows continued, with $434 million withdrawn recently, reflecting reduced demand and investor caution. Although some signs of a recovery base are emerging, weak spot demand and shrinking inflows suggest challenges ahead for a sustained Bitcoin rebound. A broad recovery in spot demand and ETF inflows is needed to support a durable market recovery.
Bitcoin's recent speculative interest shows caution as its 7-day moving average of Open Interest fell below the 365-day average. For readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 19, 2026 14:01 WIB: out of 50 major cryptocurrencies, 36 rose and 13 fell today. Notable movers include SOL (Solana) at Rp1.905.764 with a 1-day change of +2.55% and Pluang order activity split 52% Sell / 48% Buy, CAKE (PancakeSwap) at Rp39.865 with +2.41% and 87% Sell / 13% Buy, and ENJ (Enjin Coin) at Rp490 with -2.36% and 95% Sell / 5% Buy.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
